Understanding the impact of fibrosis in heart muscle diseases
The Prognostic Significance of Fibrosis Detection in Ischemic and Non-ischemic Cardiomyopathy
This study is trying to see how detecting scarring in the heart can help understand the health of people with heart muscle diseases like cardiomyopathy and coronary artery disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Royal Brompton & Harefield NHS Foundation Trust Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT00930735 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the prognostic significance of fibrosis detection in patients with cardiomyopathy and coronary artery disease. Participants will undergo cardiovascular magnetic resonance (CMR) imaging to assess various heart parameters, including left ventricular volumes and ejection fraction, as well as detect inflammation and fibrosis through advanced imaging techniques. The study will correlate these findings with biomarkers and genetic markers to better understand their implications for heart health.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with ischaemic or non-ischaemic cardiomyopathy who can safely undergo contrast-enhanced CMR.
Not a fit: Patients with end-stage renal failure or contraindications to CMR will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and management strategies for patients with cardiomyopathy.
How similar studies have performed: Other studies have shown promising results in using CMR for assessing heart conditions, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * presence of an ischaemic or non-ischaemic cardiomyopathic process * no contraindication to contrast enhanced CMR * GFR \>30 Exclusion Criteria: * ESRF * Contraindication to CM R
Where this trial is running
London
- Royal Brompton Hospital — London, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Sanjay K Prasad, MD — Royal Brompton and Harefield Foundation Trust
- Study coordinator: Sanjay K Prasad, MD
- Email: s.prasad@rbht.nhs.uk
- Phone: +442073528121
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.